Related Experiment Video
Updated: Jun 18, 2026
Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice
Published on: March 10, 2017
Hepcidin is not a marker of chronic inflammation in atherosclerosis
Aytekin Oğuz1, Mehmet Uzunlulu, Nezih Hekim
1Department of Internal Medicine, Göztepe Training and Research Hospital, Istanbul, Turkey.
Insights
Hepcidin levels were not elevated in patients with atherosclerosis compared to healthy individuals. This study did not support hepcidin as a marker for chronic inflammation in atherosclerotic cardiovascular diseases.
Area of Science:
- Cardiovascular Science
- Inflammation Research
- Biomarker Discovery
Background:
- Atherosclerosis is an inflammatory disease.
- Hepcidin is a known indicator of inflammation.
- The role of hepcidin in atherosclerosis requires further investigation.
Purpose of the Study:
- To investigate the relationship between atherosclerosis and hepcidin levels.
- To determine if hepcidin can serve as a marker for chronic inflammation in atherosclerotic cardiovascular diseases.
Main Methods:
- Study included 75 subjects (40 atherosclerosis patients, 19 healthy controls, 16 rheumatoid arthritis with anemia controls).
- Serum hepcidin levels were measured using Hepcidin Prohormone ELISA.
- Demographic and clinical data were collected for all participants.
Main Results:
- Mean serum hepcidin levels were 243.2+/-48.8 ng/ml (atherosclerosis), 374.5+/-86.4 ng/ml (diseased controls), and 234+/-59.9 ng/ml (healthy controls).
- Hepcidin levels were significantly higher in the diseased control group compared to both the atherosclerosis patient group and healthy controls (p=0.001).
- No significant difference in hepcidin levels was observed between the atherosclerosis patient group and the healthy control group.
Conclusions:
- The study did not find elevated hepcidin levels in patients with atherosclerosis.
- Hepcidin was not supported as a biomarker for chronic inflammation in atherosclerotic cardiovascular diseases.
- Further research may be needed to explore other inflammatory markers in atherosclerosis.
Objective:
To investigate the relationship between atherosclerosis, an inflammatory disease and hepcidin, which is reported as an indicator of inflammation.
Methods:
A total of 75 subjects between 40 and 70 years of age were included in the study. The patient group consisted of 40 stable patients who had previously experienced an atherosclerotic event (18 women, 22 men; mean age 56.4+/-7.1 years). There were two control groups. The first control group consisted of 19 healthy subjects (11 women, 8 men; mean age 52.6+/- 7.4 years), while the second group included 16 patients (11 women, 5 men; mean age 56.5+/-9.3 years) with rheumatoid arthritis and anemia (diseased control group). Hepcidin measurement was performed using Hepcidin Prohormone ELISA (Solid Phase Enzyme-Linked Immunosorbent Assay) test kit.
Results:
Mean serum hepcidin levels were 243.2+/-48.8 ng/ml, 374.5+/-86.4 ng/ml, and 234+/-59.9 ng/ml in the patient group, in diseased controls, and in healthy controls, respectively. Hepcidin levels were higher in diseased controls compared to the patient group and healthy controls (p=0.001). There were no significant differences between the patient group and healthy controls.
Conclusion:
These findings did not support the hypothesis that hepcidin levels could be increased in atherosclerotic cardiovascular diseases as a marker of chronic inflammation.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
07:32Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
Published on: April 12, 2024
Related Concept Videos
01:38Inflammation
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:25Hepatitis